Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Poverty-related infectious diseases Infection and autoimmunity [N4i 3]"'
Autor:
Harparkash Kaur, Robert W. Sauerwein, Chris Drakeley, Seif Shekalaghe, Lucy C Okell, Arnold Ndaro, Collins K. Mweresa, Teun Bousema, Khalid B. Beshir, Colin J. Sutherland, Patrick Sawa, Sabah A. Omar, Henk D. F. H. Schallig, Jaffu Chilongola, Rachel Hallett
Publikováno v:
The Journal of Infectious Diseases
Journal of infectious diseases, 208(12), 2017-2024. Oxford University Press
The Journal of Infectious Diseases, 208, 2017-24
Journal of Infectious Diseases; Vol 208
The Journal of Infectious Diseases, 208, 12, pp. 2017-24
Journal of infectious diseases, 208(12), 2017-2024. Oxford University Press
The Journal of Infectious Diseases, 208, 2017-24
Journal of Infectious Diseases; Vol 208
The Journal of Infectious Diseases, 208, 12, pp. 2017-24
BACKGROUND: Parasite clearance time after artemisinin-based combination therapy (ACT) may be increasing in Asian and African settings. The association between parasite clearance following ACT and transmissibility is currently unknown. METHODS: We det
Autor:
Martin J. Boeree, Edgar J G Peters, J. van Ingen, Cecile Magis-Escurra, P.N.R. Dekhuijzen, D. van Soolingen, Wouter Hoefsloot
Publikováno v:
Hoefsloot, W, van Ingen, J, Peters, E J G, Magis-Escurra, C, Dekhuijzen, P N R, Boeree, M J & van Soolingen, D 2013, ' Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases ', Clinical Microbiology and Infection, vol. 19, no. 5, pp. 432-437 . https://doi.org/10.1111/j.1469-0691.2012.03817.x
Clinical Microbiology and Infection, 19, 5, pp. 432-7
Clinical Microbiology and Infection, 19(5), 432-437
Clinical Microbiology and Infection, 19, 432-7
Clinical Microbiology and Infection, 19, 5, pp. 432-7
Clinical Microbiology and Infection, 19(5), 432-437
Clinical Microbiology and Infection, 19, 432-7
Item does not contain fulltext Mycobacterium genavense is an opportunistic non-tuberculous mycobacterium previously mostly associated with HIV-infected patients with CD4 counts below 100/muL. In this retrospective observational study of medical chart
Autor:
Connie Erkens, Kristin Kremer, Philip Supply, Gerard de Vries, Jakko van Ingen, Anne-Marie van den Brandt, Arnout Mulder, M. M. G. G. Sebek, Rosa Sloot, Mimount Enaimi, Dick van Soolingen, Jessica L. de Beer
Publikováno v:
Journal of clinical microbiology, 51(4), 1193-1198. American Society for Microbiology
Journal of Clinical Microbiology, 51, 1193-8
Journal of Clinical Microbiology, 51, 4, pp. 1193-8
Journal of Clinical Microbiology, 51, 1193-8
Journal of Clinical Microbiology, 51, 4, pp. 1193-8
In order to switch from IS 6110 and polymorphic GC-rich repetitive sequence (PGRS) restriction fragment length polymorphism (RFLP) to 24-locus variable-number tandem-repeat (VNTR) typing of Mycobacterium tuberculosis complex isolates in the national
Autor:
Soundarapandian Velmurugan, Peter F. Billingsley, André J. A. M. van der Ven, Else M. Bijker, Stephen L. Hoffman, Theo Arens, Robert W. Sauerwein, Sumana Chakravarty, Eric R. James, Anne C. Teirlinck, Anusha Gunasekera, Meta Roestenberg, Cornelus C. Hermsen, Karina Teelen, Anja Scholzen, B. Kim Lee Sim, Guido J. H. Bastiaens
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
American Journal of Tropical Medicine and Hygiene, 88, 1, pp. 5-13
American Journal of Tropical Medicine and Hygiene, 88, 5-13
American Journal of Tropical Medicine and Hygiene, 88, 1, pp. 5-13
American Journal of Tropical Medicine and Hygiene, 88, 5-13
Controlled human malaria infection with sporozoites is a standardized and powerful tool for evaluation of malaria vaccine and drug efficacy but so far only applied by exposure to bites of Plasmodium falciparum (Pf)-infected mosquitoes. We assessed in
Autor:
Ben J. Marais, R. de Groot, Monique H. Reijers, D. van Soolingen, I.L. Tuinman, Melanie Wattenberg, Martin J. Boeree, K. van den Driessche, Mark F. Cotton, Cecile Magis-Escurra
Publikováno v:
International Journal of Tuberculosis and Lung Disease, 17, 1, pp. 46-53
International Journal of Tuberculosis and Lung Disease, 1, 17, 46-53+i
International Journal of Tuberculosis and Lung Disease, 17, 46-53
International Journal of Tuberculosis and Lung Disease, 1, 17, 46-53+i
International Journal of Tuberculosis and Lung Disease, 17, 46-53
Item does not contain fulltext BACKGROUND: 'Covering your cough' reduces droplet number, but its effect on airborne pathogen transmission is less clear. The World Health Organization specifically recommends cough etiquette to prevent the spread of My
Autor:
Jos G. W. Kosterink, Noor Alsaad, Dick van Soolingen, Wiel C M de Lange, Arianna D. Pranger, Jan-Willem C. Alffenaar, Richard van Altena, Tjip S. van der Werf
Publikováno v:
European Respiratory Journal, 42, 504-12
European Respiratory Journal, 42, 2, pp. 504-12
European Respiratory Journal, 42(2), 504-512. EUROPEAN RESPIRATORY SOC JOURNALS LTD
European Respiratory Journal, 42, 2, pp. 504-12
European Respiratory Journal, 42(2), 504-512. EUROPEAN RESPIRATORY SOC JOURNALS LTD
Item does not contain fulltext Co-trimoxazole (SXT), a combination of sulfamethoxazole and trimethoprim, has shown in vitro activity against Mycobacterium tuberculosis. However, the pharmacokinetic and pharmacodynamic parameters of SXT in multidrug-r
Autor:
Henri A. Verbrugh, Marian T. ten Kate, Rob E. Aarnoutse, Dick van Soolingen, Gerjo J. de Knegt, Martin J. Boeree, Irma A. J. M. Bakker-Woudenberg, Jurriaan E. M. de Steenwinkel, Marga Teulen
Publikováno v:
American Journal of Respiratory and Critical Care Medicine, 187, 1127-34
American Journal of Respiratory and Critical Care Medicine, 187, 10, pp. 1127-34
American Journal of Respiratory and Critical Care Medicine, 187(10), 1127-1134. American Thoracic Society
American Journal of Respiratory and Critical Care Medicine, 187, 10, pp. 1127-34
American Journal of Respiratory and Critical Care Medicine, 187(10), 1127-1134. American Thoracic Society
Item does not contain fulltext Rationale: The dosage of 10 mg/kg/d rifampin, as currently used in the treatment of tuberculosis (TB), is not an optimal dose. Shortening of treatment duration might be achievable using an increased rifampin dose. Objec
Autor:
van der Schaar, H.M., Leyssen, Pieter, Thibaut, H.J., de Palma, Armando, van der Linden, Lonneke, Lanke, Kjerstin H.W., Lacroix, Céline, Verbeken, Erik, Conrath, Katja, Macleod, Angus M, Mitchell, Dale R, Palmer, Nicholas J, van de Poël, Hervé, Andrews, Martin, Neyts, Johan, van Kuppeveld, F.J.M., Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I SIB1
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 57, 4971-81
Antimicrobial Agents and Chemotherapy, 57(10), 4971. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 57, pp. 4971-81
Antimicrobial Agents and Chemotherapy, 57, 4971-81
Antimicrobial Agents and Chemotherapy, 57(10), 4971. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 57, pp. 4971-81
Despite their high clinical and socioeconomic impacts, there is currently no approved antiviral therapy for the prophylaxis or treatment of enterovirus infections. Here we report on a novel inhibitor of enterovirus replication, compound 1, 2-fluoro-4
Autor:
Martien W. Borgdorff, D. van Soolingen
Publikováno v:
Clinical Microbiology and Infection, 19, 889-901
Clinical Microbiology and Infection, 19, 10, pp. 889-901
Clinical Microbiology and Infection, 19, 10, pp. 889-901
Item does not contain fulltext Tuberculosis (TB) has re-emerged over the past two decades: in industrialized countries in association with immigration, and in Africa owing to the human immunodeficiency virus epidemic. Drug-resistant TB is a major thr
Autor:
Henri A. Verbrugh, Marian T. ten Kate, Jurriaan E. M. de Steenwinkel, Gerjo J. de Knegt, Martin J. Boeree, Rob E. Aarnoutse, Irma A. J. M. Bakker-Woudenberg, Michael A. den Bakker, Dick van Soolingen
Publikováno v:
Antimicrobial Agents & Chemotherapy, 56(9), 4937-4944. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 56, 4937-44
Antimicrobial Agents and Chemotherapy, 56, 9, pp. 4937-44
Antimicrobial Agents and Chemotherapy, 56, 4937-44
Antimicrobial Agents and Chemotherapy, 56, 9, pp. 4937-44
Despite great effort by health organizations worldwide in fighting tuberculosis (TB), morbidity and mortality are not declining as expected. One of the reasons is related to the evolutionary development of Mycobacterium tuberculosis , in particular t